Qiagen (NYSE:QGEN) Now Covered by Analysts at Barclays

Equities research analysts at Barclays initiated coverage on shares of Qiagen (NYSE:QGEN - Get Free Report) in a research report issued to clients and investors on Tuesday,Briefing.com Automated Import reports. The brokerage set an "overweight" rating and a $55.00 price target on the stock. Barclays's price objective would suggest a potential upside of 17.72% from the company's current price.

Several other equities research analysts have also recently weighed in on QGEN. Wall Street Zen raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 15th. Robert W. Baird lifted their price objective on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Finally, Redburn Atlantic downgraded shares of Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Seven research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $48.77.

Qiagen Stock Down 0.1%

Shares of QGEN opened at $46.72 on Tuesday. The firm's 50-day simple moving average is $43.68 and its 200 day simple moving average is $42.41. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.83 and a current ratio of 3.37. The firm has a market cap of $10.39 billion, a P/E ratio of 117.14, a price-to-earnings-growth ratio of 2.39 and a beta of 0.67. Qiagen has a 52 week low of $37.63 and a 52 week high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.50 by $0.05. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. The company had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. During the same quarter in the prior year, the business earned $0.44 earnings per share. The firm's revenue for the quarter was up 5.2% on a year-over-year basis. On average, analysts forecast that Qiagen will post 2.26 earnings per share for the current year.

Institutional Investors Weigh In On Qiagen

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Groupama Asset Managment lifted its position in Qiagen by 8,074.0% in the 4th quarter. Groupama Asset Managment now owns 31,817,740 shares of the company's stock valued at $1,416,844,000 after acquiring an additional 32,216,761 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Qiagen by 9.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 25,319,332 shares of the company's stock worth $1,127,470,000 after buying an additional 2,202,040 shares in the last quarter. Wellington Management Group LLP raised its position in Qiagen by 12.2% in the 1st quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company's stock valued at $972,191,000 after buying an additional 2,656,136 shares during the last quarter. Vanguard Group Inc. lifted its stake in Qiagen by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 8,879,089 shares of the company's stock valued at $397,937,000 after acquiring an additional 77,119 shares in the last quarter. Finally, Deutsche Bank AG boosted its holdings in Qiagen by 57.5% during the 1st quarter. Deutsche Bank AG now owns 4,491,131 shares of the company's stock worth $180,319,000 after acquiring an additional 1,639,621 shares during the last quarter. 70.00% of the stock is owned by institutional investors.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.